

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of the Claims:**

Claims 1-21 (cancelled)

Claim 22 (New): An isolated polypeptide having at least 80% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 23 (New): The isolated polypeptide of Claim 22 having at least 85% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 24 (New): The isolated polypeptide of Claim 22 having at least 90% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 25 (New): The isolated polypeptide of Claim 22 having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);

- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 26 (New): The isolated polypeptide of Claim 22 having at least 99% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) [the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621;

wherein the polypeptide is able to inhibit proliferation of stimulated T-lymphocytes.

Claim 27 (New): A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.

Claim 28 (New): The chimeric polypeptide of Claim 27, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Claim 29 (New): An isolated chitinase polypeptide having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 30 (New): A chimeric polypeptide comprising a polypeptide according to Claim 29 fused to a heterologous polypeptide.

Claim 31 (New): The chimeric polypeptide of Claim 30, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Claim 32 (New): An isolated mucin polypeptide having at least 95% sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO:83);
- (b) the amino acid sequence of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 32 (SEQ ID NO: 83), lacking its associated signal peptide;  
or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209621.

Claim 33 (New): A chimeric polypeptide comprising a polypeptide according to Claim 32 fused to a heterologous polypeptide.

Claim 34 (New): The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.